Semaglutide vs Tirzepatide: Complete Comparison

Semaglutide and Tirzepatide are the two most prescribed injectable medications for weight loss and type 2 diabetes. Both have demonstrated unprecedented results in clinical trials, but they work through different mechanisms and have meaningful differences in efficacy, side effects, and availability. This guide breaks down everything you need to know.

Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which is naturally released after eating. GLP-1 signals the brain to reduce appetite, slows stomach emptying, and enhances insulin secretion. Semaglutide is a single-target drug — it activates one receptor system.

Tirzepatide (brand names: Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism provides appetite suppression through GLP-1 while GIP activation improves insulin sensitivity, enhances fat metabolism, and may contribute additional weight loss effects that GLP-1 alone does not provide.

In head-to-head clinical trials, Tirzepatide consistently produces greater weight loss than Semaglutide.

Semaglutide (Wegovy 2.4 mg): The STEP trials showed average weight loss of 15-17% of body weight over 68 weeks.

Tirzepatide (Zepbound 15 mg): The SURMOUNT trials showed average weight loss of 20-22% of body weight over 72 weeks. At the highest dose, some participants lost over 25% of their body weight.

The approximately 5-7 percentage point difference is clinically significant and represents the main advantage of Tirzepatide over Semaglutide for weight management.

Both medications are highly effective for type 2 diabetes. Semaglutide (Ozempic) typically reduces HbA1c by 1.5-1.8%. Tirzepatide (Mounjaro) reduces HbA1c by 2.0-2.4%, making it the most effective glucose-lowering injectable currently available.

Tirzepatide's dual mechanism gives it an edge for blood sugar control. The GIP receptor activation provides additional insulin sensitization that complements the GLP-1 effects. Both medications have also shown cardiovascular benefits in clinical trials.

The side effect profiles are similar, dominated by gastrointestinal symptoms:

Semaglutide: Nausea (30-45% of users), vomiting, diarrhea, constipation. These usually improve after the first few weeks. Serious risks include pancreatitis, gallstones, and kidney problems from dehydration.

Tirzepatide: Nausea (25-35%), diarrhea, constipation, vomiting. The slightly lower nausea rate may be due to GIP's gastroprotective effects. Serious risks are similar: pancreatitis, gallstones, gastroparesis.

Both carry a boxed warning about thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with a family history of medullary thyroid carcinoma.

Muscle loss alongside fat loss is a concern with both medications. Resistance training and adequate protein intake are recommended during treatment.

Semaglutide: Injected subcutaneously once weekly. Weight loss dose escalation: start at 0.25 mg, increase every 4 weeks to maintenance of 2.4 mg. An oral form (Rybelsus) is available for diabetes but at lower doses.

Tirzepatide: Injected subcutaneously once weekly. Dose escalation: start at 2.5 mg, increase by 2.5 mg every 4 weeks to maintenance of 5-15 mg.

Both require gradual dose escalation to minimize gastrointestinal side effects.

Tirzepatide produces greater weight loss and better blood sugar control than Semaglutide in clinical trials. However, Semaglutide has a longer track record, more published safety data, an oral option, and may be more accessible depending on insurance coverage and availability.

For maximum weight loss: Tirzepatide has the clinical edge. For an oral option: Semaglutide (Rybelsus) is the only one available. For established safety data: Semaglutide has been on the market longer.

Both are prescription medications that require medical supervision. The choice between them should be made with a healthcare provider based on individual health profile, goals, and insurance coverage.